CSIMarket.com presents a summary of the promising results from Shattuck Labs’ Phase 1B dose expansion clinical trial involving SL-172154 and Azacitidine (AZA) in frontline higher-risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients. With the release of data at the European Hematology Association (EHA) 2024 Congress, this article aims to ly outline the facts surrounding observed complete response rates and successful bridging to hematopoietic cell transplantation.
:
The of this article is to provide an overview of the key findings from the Phase 1B dose expansion clinical trial conducted by Shattuck Labs, highlighting the encouraging complete response rates achieved in previously untreated HR-MDS and TP53m AML patients. Additionally, the successful bridging of responding TP53m AML patients to hematopoietic cell transplantation will be discussed, showcasing the potential of SL-172154 and Azacitidine in improving treatment outcomes.
Key Findings
As of the February 1, 2024, data cutoff, the trial showed encouraging complete response rates in previously untreated HR-MDS and TP53m AML patients. The combination of SL-172154 with Azacitidine demonstrated strong potential in achieving complete responses among these higher-risk patients, a significant milestone in improving prognosis and survival rates.
Furthermore, the study showcased successful bridging of responding TP53m AML patients to hematopoietic cell transplantation. This finding highlights the potential of SL-172154 to serve as a bridge therapy, restoring favorable conditions for successful transplantation procedures in this subset of patients. Successful transplantation is crucial for improved long-term outcomes, making this finding particularly noteworthy.
Conclusion:
The Phase 1B dose expansion clinical trial of SL-172154 with Azacitidine has shown promising results in frontline higher-risk Myelodysplastic Syndromes and TP53 mutant Acute Myeloid Leukemia patients. The observed complete response rates and successful bridging of responding TP53m AML patients to hematopoietic cell transplantation signify the potential of this combination therapy to improve treatment outcomes and prognosis in these challenging conditions. Further research and larger-scale trials are warranted to validate these findings and explore the full therapeutic potential of SL-172154 in HR-MDS and TP53m AML.
Comments